NASDAQ:DERM Journey Medical (DERM) Stock Price, News & Analysis → Automatic Income (from home) (From Awesomely, LLC) (Ad) Free derm Stock Alerts $3.69 +0.06 (+1.65%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$3.52▼$3.7350-Day Range$2.92▼$4.4252-Week Range$1.02▼$8.11Volume51,784 shsAverage Volume134,100 shsMarket Capitalization$73.54 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Journey Medical alerts: Email Address Journey Medical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.4% Upside$8.50 Price TargetShort InterestHealthy3.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.33Based on 6 Articles This WeekInsider TradingAcquiring Shares$169,300 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.83) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.49 out of 5 starsMedical Sector2827th out of 5,424 stocksPharmaceutical Preparations Industry1255th out of 2,550 stocks 3.5 Analyst's Opinion Consensus RatingJourney Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageJourney Medical has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.54% of the float of Journey Medical has been sold short.Short Interest Ratio / Days to CoverJourney Medical has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Journey Medical has recently increased by 59.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldJourney Medical does not currently pay a dividend.Dividend GrowthJourney Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DERM. Previous Next 1.8 News and Social Media Coverage News SentimentJourney Medical has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Journey Medical this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for DERM on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Journey Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Journey Medical insiders have bought 1,742.62% more of their company's stock than they have sold. Specifically, they have bought $169,300.00 in company stock and sold $9,188.00 in company stock.Percentage Held by Insiders19.42% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.25% of the stock of Journey Medical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Journey Medical are expected to grow in the coming year, from ($0.83) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Journey Medical is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Journey Medical is -10.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJourney Medical has a P/B Ratio of 3.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceWatch this FREE trading tutorial while it’s still availableOn Wednesday, May 8, the legendary Jonathan Rose is holding his first ever Masters in Trading Summit. Jonathan is one of the sharpest traders I’ve ever met. He made millions trading in the pits of the world’s largest exchanges.Click here for details. About Journey Medical Stock (NASDAQ:DERM)Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Read More DERM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DERM Stock News HeadlinesMay 1, 2024 | globenewswire.comJourney Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerApril 30, 2024 | finance.yahoo.comCrown Laboratories Announces Expanded Role for Nadeem Moiz, President, Chief Operating Officer and Chief Financial OfficerMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 30, 2024 | msn.comDax Shepard Posts Clip of Kristen Bell Buzzed on Laughing Gas at DentistApril 30, 2024 | finance.yahoo.comLaserAway - Nation's Leading Aesthetic Dermatology Company - Adds Former Orangetheory CMO and Amazon Exec Kelly Lohr as Chief Customer OfficerApril 30, 2024 | msn.com15 Professions Know To Be Part Of The Upper ClassApril 29, 2024 | ca.style.yahoo.comThe Expert's Guide to Using Oils for Hair GrowthApril 26, 2024 | abcnews.go.comIsabella Strahan shares day-in-the-life amid chemotherapy, brain tumor battleMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 25, 2024 | globenewswire.comJourney Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024April 20, 2024 | yahoo.com'I Tried Out For A Reality Dating Show But Got Ghosted After My Photos Showed My Psoriasis'April 11, 2024 | msn.comMum of Little Boy with Rare 'Werewolf' Condition Claims She Ate Cat While Pregnant: "I Craved It"April 11, 2024 | msn.comProduct Of The Week: Curology Hair FormulaRxApril 9, 2024 | msn.comI'd Never Heard of Winlevi, but It's Been a Game-Changer For My AcneApril 8, 2024 | msn.comHigh tech Belfast Skin Clinic invests in latest cancer screening technologyApril 4, 2024 | msn.comGerard Butler's Brush with Danger: Hospitalized After Bee Venom Therapy MisadventureApril 4, 2024 | msn.comMillennial Skin Care: The Best Skincare Routine in Your 30sApril 3, 2024 | finance.yahoo.comOakview Dermatology Selects FluentStream’s Business Communication Services to Support Its Nine LocationsMarch 29, 2024 | msn.comWhy a new law is preventing some teens from achieving a pre-summer glowMarch 29, 2024 | msn.comTikTokers Are Selling Miles of Mouth Tape, Despite Little Scientific Evidence It Does AnythingMarch 25, 2024 | finance.yahoo.comDirector Justin Smith Acquires 30,000 Shares of Journey Medical Corp (DERM)March 23, 2024 | seekingalpha.comJourney Medical Corporation (DERM) Q4 2023 Earning Call TranscriptMarch 23, 2024 | finance.yahoo.comJourney Medical Full Year 2023 Earnings: EPS Misses ExpectationsMarch 22, 2024 | uk.investing.comJourney Medical Corp (DERM)March 22, 2024 | finance.yahoo.comQ4 2023 Journey Medical Corp Earnings CallMarch 21, 2024 | investorplace.comDERM Stock Earnings: Journey Medical Beats EPS, Beats Revenue for Q4 2023March 21, 2024 | msn.comJourney Medical GAAP EPS of -$0.21 misses by $0.02, revenue of $79.18M beats by $0.21MSee More Headlines Receive DERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Journey Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today5/04/2024Next Earnings (Estimated)5/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DERM Previous SymbolNASDAQ:DERM CUSIPN/A CIK1867066 Webjourneymedicalcorp.com Phone480-434-6670FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$8.50 Low Stock Price Target$8.50 Potential Upside/Downside+130.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,850,000.00 Net Margins-4.87% Pretax Margin-4.59% Return on Equity-34.08% Return on Assets-5.00% Debt Debt-to-Equity Ratio0.72 Current Ratio1.35 Quick Ratio1.10 Sales & Book Value Annual Sales$79.18 million Price / Sales0.93 Cash Flow$0.19 per share Price / Cash Flow19.37 Book Value$1.05 per share Price / Book3.51Miscellaneous Outstanding Shares19,930,000Free Float16,061,000Market Cap$73.54 million OptionableN/A Beta0.78 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Lindsay Allan Rosenwald (Age 69)Executive Chairman Comp: $50kMr. Claude Maraoui (Age 57)Founder, President, CEO & Director Comp: $820.3kMr. Joseph M. Benesch (Age 57)Interim CFO & Corporate Controller Mr. Andrew J. ZwibleVice President of OperationsMr. Ramsey Alloush (Age 38)General Counsel & Company Secretary Mr. Robert Nevin (Age 56)Chief Commercial Officer Jaclyn JaffeSenior Director of Corporate OperationsMore ExecutivesKey CompetitorsAssembly BiosciencesNASDAQ:ASMBvTv TherapeuticsNASDAQ:VTVTLandos BiopharmaNASDAQ:LABPRallybioNASDAQ:RLYBYS BiopharmaNASDAQ:YSView All CompetitorsInsidersLindsay A Md RosenwaldBought 10,000 shares on 3/25/2024Total: $30,400.00 ($3.04/share)Claude MaraouiBought 10,000 shares on 3/22/2024Total: $34,800.00 ($3.48/share)Justin Adam SmithBought 30,000 shares on 3/22/2024Total: $104,100.00 ($3.47/share)Joseph BeneschSold 2,450 sharesTotal: $9,187.50 ($3.75/share)View All Insider Transactions DERM Stock Analysis - Frequently Asked Questions Should I buy or sell Journey Medical stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Journey Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DERM shares. View DERM analyst ratings or view top-rated stocks. What is Journey Medical's stock price target for 2024? 1 analysts have issued 12 month price targets for Journey Medical's stock. Their DERM share price targets range from $8.50 to $8.50. On average, they anticipate the company's share price to reach $8.50 in the next year. This suggests a possible upside of 130.4% from the stock's current price. View analysts price targets for DERM or view top-rated stocks among Wall Street analysts. How have DERM shares performed in 2024? Journey Medical's stock was trading at $4.82 on January 1st, 2024. Since then, DERM stock has decreased by 23.4% and is now trading at $3.69. View the best growth stocks for 2024 here. Are investors shorting Journey Medical? Journey Medical saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 235,500 shares, an increase of 59.0% from the March 31st total of 148,100 shares. Based on an average daily volume of 171,700 shares, the days-to-cover ratio is presently 1.4 days. Currently, 3.5% of the shares of the company are short sold. View Journey Medical's Short Interest. When is Journey Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our DERM earnings forecast. How were Journey Medical's earnings last quarter? Journey Medical Co. (NASDAQ:DERM) issued its quarterly earnings data on Thursday, March, 21st. The company reported ($0.12) EPS for the quarter. The firm earned $15.26 million during the quarter, compared to analysts' expectations of $15.80 million. Journey Medical had a negative net margin of 4.87% and a negative trailing twelve-month return on equity of 34.08%. What other stocks do shareholders of Journey Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Journey Medical investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Novavax (NVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), Karyopharm Therapeutics (KPTI), Pfizer (PFE), AT&T (T), Exelixis (EXEL) and ImmunoGen (IMGN). When did Journey Medical IPO? Journey Medical (DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at $10.00-$12.00 per share. How do I buy shares of Journey Medical? Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DERM) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchStock-Picking AI Predicts #1 Stock of 2024AltimetryHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
